These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 20933199

  • 1. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The funny current: cellular basis for the control of heart rate.
    DiFrancesco D, Borer JS.
    Drugs; 2007; 67 Suppl 2():15-24. PubMed ID: 17999560
    [Abstract] [Full Text] [Related]

  • 4. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 5. Ivabradine: from molecular basis to clinical effectiveness.
    Riccioni G.
    Adv Ther; 2010 Mar; 27(3):160-7. PubMed ID: 20419486
    [Abstract] [Full Text] [Related]

  • 6. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK, Gray D, Purcell H.
    Adv Ther; 2009 Feb; 26(2):127-37. PubMed ID: 19259630
    [Abstract] [Full Text] [Related]

  • 7. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J.
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [Abstract] [Full Text] [Related]

  • 8. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E, Bonadei I, D'Aloia A, Del Magro F, Piovanelli B, Bontempi L, Curnis A, Dei Cas L.
    Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
    [Abstract] [Full Text] [Related]

  • 9. Pacemaker activity of the human sinoatrial node: role of the hyperpolarization-activated current, I(f).
    Verkerk AO, van Ginneken AC, Wilders R.
    Int J Cardiol; 2009 Mar 06; 132(3):318-36. PubMed ID: 19181406
    [Abstract] [Full Text] [Related]

  • 10. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Mar 06; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 11. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar 06; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 12. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS, Le Heuzey JY.
    Am J Ther; 2008 Mar 06; 15(5):461-73. PubMed ID: 18806523
    [Abstract] [Full Text] [Related]

  • 13. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM, Vitale C, Volterrani M.
    Adv Ther; 2010 Apr 06; 27(4):202-10. PubMed ID: 20495895
    [Abstract] [Full Text] [Related]

  • 14. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.
    Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D.
    J Physiol; 2006 Apr 15; 572(Pt 2):335-46. PubMed ID: 16484306
    [Abstract] [Full Text] [Related]

  • 15. The cardiac pacemaker current.
    Baruscotti M, Barbuti A, Bucchi A.
    J Mol Cell Cardiol; 2010 Jan 15; 48(1):55-64. PubMed ID: 19591835
    [Abstract] [Full Text] [Related]

  • 16. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.
    Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, Thorin E, Asselin C, Roméo P, Leung TK, Latour JG, Des Rosiers C, Bouly M, Rhéaume E, Tardif JC.
    Cardiology; 2010 Jan 15; 117(3):234-42. PubMed ID: 21212673
    [Abstract] [Full Text] [Related]

  • 17. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S, Timmis AD.
    Int J Clin Pract; 2006 Feb 15; 60(2):222-8. PubMed ID: 16451297
    [Abstract] [Full Text] [Related]

  • 18. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC, Reil GH, Böhm M.
    Trends Cardiovasc Med; 2009 Jul 15; 19(5):152-7. PubMed ID: 20005474
    [Abstract] [Full Text] [Related]

  • 19. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009 Jul 15; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 20. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R, Ceconi C.
    Expert Rev Cardiovasc Ther; 2011 Aug 15; 9(8):959-73. PubMed ID: 21878041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.